Clinical Trials
22 trialsNCT01724866 2022-04-15
Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT02190721 2021-12-10
A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT03251768 2019-09-13
Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients
Tianjin SinoBiotech Ltd.
Phase 2 Completed
NCT02544685 2019-01-17
FENSY
S&D Pharma SK s.r.o.
Phase 2 Unknown
NCT01648322 2018-10-03
Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 2 Completed
NCT02282215 2018-09-27
Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia
Cellerant Therapeutics
Phase 2 Completed
NCT02005458 2018-07-17
Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
Xiamen Amoytop Biotech Co., Ltd.
Phase 2 Completed
NCT02521441 2018-02-23
A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.
EVIVE Biotechnology
Phase 2 Completed
NCT00771810 2017-11-13
Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer
Tarix Pharmaceuticals
Phase 2 Completed
NCT00364468 2017-03-03
Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT01569087 2016-12-05
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
Biocad
Phase 2 Completed
NCT02778763 2016-07-20
Study on Efficacy and Safety of CBLB612 for Neutropenia Prophylaxis
BioLab 612 LLC
Phase 2 Completed
NCT02119715 2014-04-22
A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT00115193 2013-08-29
Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma
Amgen
Phase 2 Completed
NCT00497809 2011-05-03
Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia
AviGenics
Phase 2 Completed
NCT00035620 2010-02-26
Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy
Amgen
Phase 2 Completed
NCT00124111 2010-02-26
A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer
Amgen
Phase 2 Completed
NCT00117897 2009-07-20
Treatment for Subjects With Non-Hodgkin's Lymphoma
Amgen
Phase 2 Completed
NCT00113789 2009-02-13
Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer
Amgen
Phase 2 Completed
NCT00114764 2008-10-31
Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)
Amgen
Phase 2 Completed
NCT00115414 2008-08-01
Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)
Amgen
Phase 2 Completed
NCT00501332 2007-12-24
Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy
Maxygen Holdings Ltd.
Phase 2 Unknown